Cancer

Presence of leukemia cutis tied to worse survival in AML

(HealthDay)—For patients with acute myeloid leukemia (AML), the presence of leukemia cutis (LC) is associated with decreased overall and leukemia-specific survival, according to a study published online April 10 in JAMA ...

Cancer

Starving leukemia cells by targeting amino acids

Cancer cells consume sugar at a higher rate than healthy cells, but they're also hungry for amino acids, the building blocks of proteins and other biomolecules. Researchers at Winship Cancer Institute of Emory University ...

HIV & AIDS

A cure for HIV? Feasible but not yet realized

This week a team of scientists and physicians from the U.K. published news of a second HIV positive man, in London, who is in long-term (18-month) HIV remission after undergoing treatment for Hodgkins lymphoma. The unexpected ...

Cancer

New therapy for aggressive blood cancer discovered

Researchers at Vetmeduni Vienna and Ludwig Boltzmann Institute for Cancer Research have identified a new therapeutic strategy foR acute myeloid leukemia. They found that the activity of the mutated oncogenic protein C/EBPα ...

Cancer

Cancer causes premature ageing

Leukaemia promotes premature ageing in healthy bone marrow cells—according to new research from the University of East Anglia.

page 1 from 23

Acute myeloid leukemia

Acute myeloid leukemia (AML), also known as acute myelogenous leukemia, is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Although AML is a relatively rare disease, accounting for approximately 1.2% of cancer deaths in the United States, its incidence is expected to increase as the population ages.

The symptoms of AML are caused by replacement of normal bone marrow with leukemic cells, which causes a drop in red blood cells, platelets, and normal white blood cells. These symptoms include fatigue, shortness of breath, easy bruising and bleeding, and increased risk of infection. Although several risk factors for AML have been identified, the specific cause of the disease remains unclear. As an acute leukemia, AML progresses rapidly and is typically fatal within weeks or months if left untreated.

AML has several subtypes; treatment and prognosis varies among subtypes. 5-year survival varies from 15-70%, and relapse rate varies from 78-33%, depending on subtype. AML is treated initially with chemotherapy aimed at inducing a remission; patients may go on to receive additional chemotherapy or a hematopoietic stem cell transplant. Recent research into the genetics of AML has developed tests that better predict how long a patient is likely to survive and whether a drug is likely to be effective.

This text uses material from Wikipedia, licensed under CC BY-SA